Treace Medical ConceptsTMCI
TMCI
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
736% more call options, than puts
Call options by funds: $1.21M | Put options by funds: $145K
18% more capital invested
Capital invested by funds: $235M [Q3] → $278M (+$42.8M) [Q4]
18% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 22
2% more funds holding
Funds holding: 132 [Q3] → 134 (+2) [Q4]
7% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 45
5.26% less ownership
Funds ownership: 65.14% [Q3] → 59.88% (-5.26%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$9.50
18%
upside
Avg. target
$9.50
18%
upside
High target
$9.50
18%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Truist Securities Richard Newitter 51% 1-year accuracy 22 / 43 met price target | 18%upside $9.50 | Hold Maintained | 13 Mar 2025 |
Financial journalist opinion
Based on 3 articles about TMCI published over the past 30 days
Neutral
GlobeNewsWire
4 days ago
Treace Announces Clinical Study Data Demonstrating Positive Lapiplasty® and Adductoplasty® Outcomes at the 2025 ACFAS Annual Scientific Conference
PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced the presentation of updated interim data for the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies, as well as the first presentation of the MTA3D™ Adductoplasty® clinical study, at the 2025 American College of Foot and Ankle Surgeons (ACFAS) Annual Meeting in Phoenix, Arizona.
Neutral
GlobeNewsWire
6 days ago
Treace Highlights New Innovations at the 2025 ACFAS Annual Scientific Conference
Expands market-leading position with new best-in-class bunion technologies Expands market-leading position with new best-in-class bunion technologies
Neutral
Accesswire
4 weeks ago
An Investigation Has Been Launched Into Treace Medical Concepts, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
1 month ago
The Schall Law Firm Invites Investors With Losses In Treace Medical Concepts, Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Seeking Alpha
1 month ago
Treace Medical Concepts, Inc. (TMCI) Q4 2024 Earnings Call Transcript
Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Vivian Cervantes - Investor Relations, Gilmartin Group John Treace - Chief Executive Officer Mark Hair - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Lily Lozada - JPMorgan Kallum Titchmarsh - Morgan Stanley Richard Newitter - Truist Securities Danielle Antalffy - UBS Ben Haynor - Lake Street Capital Markets Operator Welcome to the Treace Medical Concepts Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Neutral
Accesswire
1 month ago
An Investigation Has Been Launched Into Treace Medical Concepts, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Negative
Zacks Investment Research
1 month ago
Treace Medical Concepts (TMCI) Reports Q4 Loss, Tops Revenue Estimates
Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.10 per share a year ago.
Neutral
Accesswire
1 month ago
An Investigation Has Been Launched Into Treace Medical Concepts, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 26, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
1 month ago
The Schall Law Firm Invites Investors With Losses In Treace Medical Concepts, Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / February 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
1 month ago
An Investigation Has Been Launched Into Treace Medical Concepts, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Charts implemented using Lightweight Charts™